More Stories

Informist, Tuesday, Aug. 12, 2025

By P.Madhu Kumar

MUMBAI – Zydus Lifesciences Ltd. reported a better-than-expected June quarter earnings aided by India formulations and International market sales, and a sharp rise in its other income which supported the consolidated net profit of the company. The company reported an on-year rise of 3.3% in its consolidated net profit to INR 14.67 billion in Apr-Jun against the analysts expectations of a 3.92% on-year fall to INR 13.6 billion for the reporting quarter.

The drugmaker's net sales rose nearly 6% on year to INR 65.74 billion in the June quarter and it was the company's slowest on year top line growth since Jan-Mar 2024. Analysts had expected its net revenue to grow 5.2% on year to INR 65.3 billion in the latest quarter. 

The company's consolidated earnings before interest, tax, depreciation, and amortisation hardly changed and came in at INR 20.89 billion compared with INR 20.84 billion from the year-ago period. Zydus Life's EBITDA margin stood at 31.8% in the June quarter as against 33.6% in the year ago quarter. More

The Ahmedabad-based company's consolidated revenue from its pharmaceuticals segment rose over 6% on year to INR 57.16 billion for the reporting quarter and the consumer products revenue gained marginally on year to INR 8.58 billion as compared to INR 8.38 billion from the year ago quarter. 

The company's India formulations sales rose 8% on year to INR 15.20 billion backed by growth in its chronic segment, pillar brands and innovation portfolio. The share of its chronic portfolio in India formulations business has gone up consistently over the years and stood at 43.7%, which is an improvement of 420 basis points over the last three years, the company said in a press release. The India formulations business accounted for around 24% of the consolidated revenues of the company in Apr-Jun. 

The US formulations sales of Zydus Life rose nearly 3% on year to INR 31.82 billion. Sales from the region for the period was $372 million compared with $371 million in the year-ago period, in constant currency terms. The US formulations business contributed to 49% of the top line of the company. 

The company's international formulation sales went up by a staggering 37% on year to INR 7.27 billion driven by an all-round growth and strong demand across key geographies. The company said that its organic capital expenditure for the June quarter was of INR 4.02 billion and the net cash stood at INR 56.31 billion as of Jun. 30, higher than INR 48.84 billion as of Mar. 31. On Tuesday, shares of Zydus Lifesciences closed flat at INR 955.65, on the National Stock Exchange.  End

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

Edited by Akul Nishant Akhoury

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.